Vir Biotechnology, Inc. (VIR): Revenue
$68.56M
Year ended 2025-12-31
$303.23M
Trailing 12 months to 2026-06-30
-65.1%
3-year compound annual growth
-2.1%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $68.56M | -7.6% | 2026-02-23, From 2025-01-01 |
| 2024-12-31 | $74.20M | -13.9% | 2026-02-23, From 2024-01-01 |
| 2023-12-31 | $86.18M | -94.7% | 2026-02-23, From 2023-01-01 |
| 2022-12-31 | $1.62B | +47.5% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $1.10B | n/m | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $76.37M | +843.9% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $8.09M | -24.2% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $10.67M | +293.9% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $2.71M | n/a | 2020-03-26, From 2017-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $68.56M | -7.6% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $70.00M | n/a |
| Compugen Ltd (CGEN) | 2025-12-31 | $72.76M | +161.1% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $74.68M | +26.9% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $75.39M | +644.9% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $59.42M | +4.4% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $81.39M | +144.6% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $85.21M | n/m |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $53.43M | +110.5% |
Compare VIR, BDTX, CGEN, RXRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗